'Austin et al.

Application No.: 09/834,760

Page 4

Attorney Docket No.: 19874-000410US

1321 GATTCCAAGG AACACAGTGG TGCCTACCAA GAAGTCTCAG ATCTTTCTA CAGCTTCTGA
1381 TAATCAACCA ACTGTTACAA TCAAGGTCTA TGAAGGTGAA AGACCCCTGA CAAAAGACAA
1441 TCATCTTCTG GGTACATTG ATCTGACTGG AATTCCTCCT GCTCCTCGTG GGGTCCCACA
1501 GATTGAAGTC ACCTTTGAGA TAGATGTGAA TGGTATTCTT CGAGTGACAG CTGAAGACAA
1561 GGGTACAGGG AACAAAAATA AGATCACAAT CACCAATGAC CAGAATCGCC TGACACCTGA
1621 AGAAATCGAA AGGATGGTTA ATGATGCTGA GAAGTTTGCT GAGGAAGACA AAAAGCTCAA
1681 GGAGCGCATT GATACTAGAA ATGAGTTGGA AAGCTATGCC TATTCCTTAA AGAATCAGAT
1741 TGGAGATAAA GAAAAGCTGG GAGGTAAACT TTCCTCTGAA GATAAGGAGA CCATGGAAAA
1801 AGCTGTAGAA GAAAAGATTG AATGGCTGGA AAGCCACCAA GATGCTGACA TTGAAGACTT
1861 CAAAGCTAAG AAGAAGGAAC TGGAAGAAAT TGTTCAACCA ATTATCAGCA AACTCTATGG
1921 AAGTGCAGGC CCTCCCCCAA CTGGTGAAGA GGATACAGCA GAAAAAGATG AGTTGTAGAC
1981 ACTGATCTGC TAGTGCTGTA ATATTGT

Please insert the accompanying paper copy of the Sequence Listing, page numbers 1 through 4, at the end of the application and renumber the pages of the application accordingly.

#### **REMARKS**

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above named sequences, SEQ ID NOS:1-5, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.

Attached hereto is a marked-up version of the changes made to the specification by the amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

'Austin et al.

Application No.: 09/834,760

Page 5

**PATENT** Attorney Docket No.: 19874-000410US

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834 Tel: (415) 576-0200 Fax: (415) 576-0300

EGW:adm PA 3171018 v1 dg. No. 37,336

Austin et al. Application No.: 09/834,760

Application No.: 09/8 Page 6

PATENT Attorney Docket No.: 19874-000410US

# VERSION WITH MARKINGS TO SHOW CHANGES MADE

# In the Specification:

The paragraph beginning on page 38, line 2 has been amended as follows:

To obtain cells stably expressing GRP78/BiP, T24/83 cells were transfected with either the mammalian cell expression vector pcDNA3.1(+) or pcDNA3.1(+) containing the open reading frame of human GRP78/BiP. The latter vector was obtained by amplifying the cDNA encoding the open-reading frame of human GRP78/BiP (approximately 1.95 kb) by reverse transcriptase-PCR using total RNA from primary HUVEC. GRP78/BiP cDNA was generated using SuperScript RNase H reverse transcriptase (Gibco/BRL) and a primer complimentary to a sequence in the 3'-untranslated region of the human GRP78/BiP mRNA transcript (AB10230; 5'-TATTACAGCACTAGCAGATCAGTG-3')(SEQ ID NO:1). For PCR amplification, the forward primer AB10231 (5'-

CTT<u>AAGCTT</u>GCCACCATGAAGCTCTCCCTGGTGGCCGCG-3') (SEQ ID NO:2) contained a Kozak consensus sequence (bold) prior to the initiating ATG and a terminal *Hind*III restriction site (underlined). The reverse primer AB10232 (5'-

AGGCCTCGAGCTACAACTCATCTTTTTCTGCTGT-3') (SEQ ID NO:3) contained a terminal *Xho*I restriction site (underlined) adjacent to the authentic termination codon of the GRP78/BiP cDNA. PCR reactions took place in a final volume of 50 μl containing 2 μl of the RT reaction, 100 ng of primers, 2.5 U *Taq* polymerase (Perkin-Elmer, Mississauga, ON) in a buffer consisting of 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, 10 mM Tris-HCl (pH 8.8) and 0.5 mM of each dNTP. All samples were subjected to amplification in a DNA thermal cycler 480 (Perkin-Elmer) with a step programme of 30 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min. The amplified GRP78/BiP cDNA was separated on a 0.8% agarose-TBE gel containing ethidium bromide, purified from the agarose gel using the QIAEX gel extraction kit (Qiagen, Mississauga, ON) and ligated into T-ended pBluescript (KS) (Stratagene, La Jolla, CA). The ligation mixture was then used to transform competent DH5α cells (Gibco/BRL). Plasmid DNA was isolated from transformed cells using the QIAEX miniprep kit (Qiagen), digested with *Hind*III and *Xho*I, and the GRP78/BiP cDNA insert purified from agarose. The GRP78/BiP cDNA insert was ligated into the *Hind*III/XhoI site of the mammalian expression vector pcDNA3.1(+) (Invitrogen, Carlsbad, CA) to produce the

Austin et al.
Application No.: 09/834,760
Page 7

PATENT Attorney Docket No.: 19874-000410US

recombinant plasmid, pcDNA3.1(+)-GRP78/BiP. Authenticity of the GRP78/BiP cDNA sequence was confirmed by fluorescence-based double stranded DNA sequencing (MOBIX).

The paragraph beginning on page 38, line 2 has been amended as follows:

## **SEQ ID NO:**[1]4

Human GRP78/BiP amino acid sequence

MKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIAND QGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKF LPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVV TVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGG GTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNR AVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKP VQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAA VQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASD NQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAED KGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLK NQIGDKEKLGGKLSSEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELE EIVQPIISKLYGSAGPPPTGEEDTAEKDEL

The paragraph beginning on page 38, line 20 has been amended as follows:

#### **SEQ ID NO:[2]5**

#### Human GRP78/BiP mRNA sequence

ACTGGCTGGC AAGATGAAGC TCTCCCTGGT GGCCGCGATG CTGCTGCTG TCAGCGCGGC GCGGGCCGAG GCGGGCCGAG GAGGAGGACA AGAAGGAGGA CGTGGGCACG GTGGTCGGCA TCGACCTGGG 121 GACCACCTAC TCCTGCGTCG GCGTGTTCAA GAACGGCCGC GTGGAGATCA TCGCCAACGA 181 TCAGGGCAAC CGCATCACGC CGTCCTATGT CGCCTTCACT CCTGAAGGGG AACGTCTGAT 141 TGGCGATGCC GCCAACGACCA AGCTCACCT CAACCCCGAG AACACGGTCT TTGACGCCAA 301 GCGGCTCATC GGCCGACGT GGAATGACCC GTCTGTGCAG CAGGACATCA AGTTCTTGCC 361 GTTCAAGGTG GTTGAAAAGA AAACTAAACC ATACATTCAA GTTGATATTG GAGGTGGGCA 421 AACAAAGACA TTTGCTCCTG AAGAAATTTC TGCCATGGTT CTCACTAAAA TGAAAGAAAC 481 CGCTGAGGCT TATTTGGGAA AGAAGGTTAC CCATGCAGTT GTTACTGTAC CAGCCTATTT 541 TAATGATGCC CAACGCCAAG CAACCAAAGA CGCTGGAACT ATTGCTGGCC TAAATGTTAT 601 GAGGATCATC AACGAGCCTA CGGCAGCTG TATTTGCTTAT GGCCTGGATA AGAGGGAGGG

Austin et al. Application No.: 09/834,760 Page 8 PATENT Attorney Docket No.: 19874-000410US

661 GGAGAAGAAC ATCCTGGTGT TTGACCTGGG TGGCGGAACC TTCGATGTGT CTCTTCTCAC 721 CATTGACAAT GGTGTCTTCG AAGTTGTGGC CACTAATGGA GATACTCATC TGGGTGGAGA 781 AGACTTTGAC CAGCGTGTCA TGGAACACTT CATCAAACTG TACAAAAAGA AGACGGGCAA 841 AGATGTCAGG AAAGACAATA GAGCTGTGCA GAAACTCCGG CGCGAGGTAG AAAAGGCCAA 901 ACGGGCCCTG TCTTCTCAGC ATCAAGCAAG AATTGAAATT GAGTCCTTCT ATGAAGGAGA 961 AGACTTTTCT GAGACCCTGA CTCGGGCCAA ATTTGAAGAG CTCAACATGG ATCTGTTCCG 1021 GTCTACTATG AAGCCCGTCC AGAAAGTGTT GGAAGATTCT GATTTGAAGA AGTCTGATAT 1081 TGATGAAATT GTTCTTGTTG GTGGCTCGAC TCGAATTCCA AAGATTCAGC AACTGGTTAA 1141 AGAGTTCTTC AATGGCAAGG AACCATCCCG TGGCATAAAC CCAGATGAAG CTGTAGCGTA 1201 TGGTGCTGCT GTCCAGGCTG GTGTGCTCTC TGGTGATCAA GATACAGGTG ACCTGGTACT 1261 GCTTGATGTA TGTCCCCTTA CACTTGGTAT TGAAACTGTG GGAGGTGTCA TGACCAAACT 1321 GATTCCAAGG AACACAGTGG TGCCTACCAA GAAGTCTCAG ATCTTTTCTA CAGCTTCTGA 1381 TAATCAACCA ACTGTTACAA TCAAGGTCTA TGAAGGTGAA AGACCCCTGA CAAAAGACAA 1441 TCATCTTCTG GGTACATTTG ATCTGACTGG AATTCCTCCT GCTCCTCGTG GGGTCCCACA 1501 GATTGAAGTC ACCTTTGAGA TAGATGTGAA TGGTATTCTT CGAGTGACAG CTGAAGACAA 1561 GGGTACAGGG AACAAAAATA AGATCACAAT CACCAATGAC CAGAATCGCC TGACACCTGA 1621 AGAAATCGAA AGGATGGTTA ATGATGCTGA GAAGTTTGCT GAGGAAGACA AAAAGCTCAA 1681 GGAGCGCATT GATACTAGAA ATGAGTTGGA AAGCTATGCC TATTCTCTAA AGAATCAGAT 1741 TGGAGATAAA GAAAAGCTGG GAGGTAAACT TTCCTCTGAA GATAAGGAGA CCATGGAAAA 1801 AGCTGTAGAA GAAAAGATTG AATGGCTGGA AAGCCACCAA GATGCTGACA TTGAAGACTT 1861 CAAAGCTAAG AAGAAGGAAC TGGAAGAAAT TGTTCAACCA ATTATCAGCA AACTCTATGG 1921 AAGTGCAGGC CCTCCCCCAA CTGGTGAAGA GGATACAGCA GAAAAAGATG AGTTGTAGAC 1981 ACTGATCTGC TAGTGCTGTA ATATTGT